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Serum protein changes in a rat 
model of chronic pain show a 
correlation between animal and 
humans
Elisa Bellei1,*, Antonietta Vilella2,*, Emanuela Monari1, Stefania Bergamini1, Aldo Tomasi1,3, 
Aurora Cuoghi1,3, Simona Guerzoni1, Letizia Manca2, Michele Zoli2,* & Luigi Alberto Pini1,*
In previous works we showed the overexpression of some proteins in biological fluids from patients 
suffering chronic pain. In this proteomic study we analysed serum from a rat model of neuropathic pain 
obtained by the chronic constriction injury (CCI) of sciatic nerve, at two time intervals, 2 and 5 weeks 
after the insult, to find proteins involved in the expression or mediation of pain. Sham-operated and 
CCI rats were treated with saline or indomethacin. Two weeks after ligation, we identified three serum 
proteins overexpressed in CCI rats, two of which, alpha-1-macroglobulin and vitamin D-binding protein 
(VDBP), remained increased 5 weeks post-surgery; at this time interval, we found increased levels 
of further proteins, namely apolipoprotein A-I (APOA1), apolipoprotein E (APOE), prostaglandin-H2 
D-isomerase (PTGDS) and transthyretin (TTR), that overlap the overexpressed proteins found in 
humans. Indomethacin treatment reversed the effects of ligation. The qPCR analysis showed that 
transcript levels of APOA1, APOE, PTGDS and VDBP were overexpressed in the lumbar spinal cord 
(origin of sciatic nerve), but not in the striatum (an unrelated brain region), of CCI rats treated with 
saline 5 weeks after surgery, demonstrating that the lumbar spinal cord is a possible source of these 
proteins.
Chronic pain (CP) arises from tissue injuries or inflammation, or from damages of the peripheral or central pain 
pathways (neuropathic pain). This latter is a disease state of the nervous system that can occur also in conditions 
in which there is no evident damage or inflammation (dysfunctional pain)1. CP is characterized by pain hyper-
sensitivity, that is manifested by painful responses to normally non-painful stimuli (allodynia) or by increased 
or extreme sensitivity to pain stimuli (hyperalgesia), that can persist long time after the initial injury is resolved2. 
Nociceptor inputs can activate a prolonged but reversible increase in the excitability and synaptic efficacy of neu-
rons in central nociceptive pathways, an event known as “central sensitization”, which manifests as pain hypersen-
sitivity, tactile allodynia, pressure hyperalgesia and enhanced temporal summation3. Current treatment options 
for CP have often poor activity and undesirable side effects, hence there is an urgent need to better understand the 
molecular mechanisms of CP, in order to identify objective biomarkers to improve diagnosis, therapy and drug 
development for an effective treatment of pain4. In this context, proteomics can be employed to generate protein 
maps from different samples (including body fluids and tissues) and for correlating protein expression levels with 
the investigated disease5. Moreover, the discovery, design and evaluation of new drugs are strongly dependent on 
the elucidation of protein mechanisms involved in the respective disease. In particular, neuropathic pain reflects 
both peripheral and central sensitization mechanisms, which involve transcriptional and posttranscriptional 
modifications in sensory nerves6. Recently, metabolomics and proteomics studies from our and other groups 
have been applied in the attempt to identify new promising biomarkers and processes associated with CP7–11 and 
nerve regeneration12. A great advance in understanding the mechanisms that underlie CP has come from animal 
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models of pain, which provide helpful and fundamental systems for preclinical pain studies13. A series of about 
40 different animal models of neuropathic pain, each with distinct features and mechanisms, has been developed 
to mimic specific human pain conditions, by producing diseases or causing traumatic injuries to the spinal cord 
or peripheral nerves, that lead to painful states14. One of the most widely used model of chronic neuropathic pain 
is the unilateral sciatic nerve chronic constriction injury (CCI), developed in rats by Bennet and Xie15. It consists 
in four loose ligatures around the sciatic nerve, that occlude but do not arrest epineural blood flow. It is relatively 
simple to perform and produces robust and stable pain hypersensitivity for at least one month after injury. This 
model has a certain degree of variability due to rat gender, age, diet and strain, in addition to surgical variables, 
such as the tightness of the constrictions and the type of suture material used for nerve ligation16. Despite these 
limitations, numerous studies have proved the power of this model for the understanding of the neuropathic pain 
mechanisms.
Recently, innovative proteomic analysis concerning the expression of proteins in sciatic nerves of mice sub-
jected to the CCI were performed by Vacca et al.17,18, demonstrating that the combination of proteomic methods 
with animal models of pain can help to identify pain-related proteins which may serve as diagnostic biomarkers 
or drug targets, improving the treatment of patients with CP19. In general, due to the incompleteness of genome 
sequencing for some animal species, the proteome analysis of most animals is still in the early stages, compared 
to the already well mapped human proteome. However, different methods are available to overcome this draw-
back, especially for the less characterized species, such as the homology search and the human annotation of 
BLAST-searched primary data20. However, this is not a concern for mouse and rat, since their genome has been 
completely sequenced, revealing a high homology with that of humans.
The objective of this study was to analyse, by a proteomic approach, serum samples from a rat model of neuro-
pathic pain obtained by the CCI of sciatic nerve15, at two time intervals, 2 and 5 weeks after the insult. While these 
two intervals post-injury show similar signs of neuropathic pain21, they markedly differ as regards degenerative/
regenerative processes of the sciatic nerve22. Indeed, sham-operated and CCI rats were treated with indomethacin 
between 2 and 5 weeks post-surgery, since it is a powerful medication23 and one of the most used non-steroidal 
anti-inflammatory drugs (NSAIDs) in human CP and chronic headaches10,11.
Methods
Animals and treatments. Adult male Wistar rats (Harlan Nossan, Italy) were matched for age (8 weeks) 
and weight (250–300 g). Eight groups of animals were considered (Fig. 1): four groups of rats were sacrificed 2 
weeks after surgery: two sham-operated groups, treated once with saline (n = 6) or indomethacin (Liometacen, 
indomethacin meglumine salt, obtained from Alfa Wassermann, Pescara, Italy, 2 mg/kg sc) (n = 5), and two CCI 
groups, treated once with saline (n = 6) or indomethacin (n = 7). Four groups of rats were sacrificed 5 weeks after 
surgery, chronically treated for 21 days (from day 15 to day 35 post-surgery): two sham-operated groups chron-
ically treated with saline (n = 8) or indomethacin (2 mg/kg sc/day) (n = 10), and two CCI groups chronically 
treated with saline (n = 11) or indomethacin (n = 11). All animals were sacrificed by decapitation at the same 
hour of the day to avoid the possibility that changes in protein expression levels can be attributed to circadian 
rhythms, 6 h after the last treatment. All efforts were made to minimize animal suffering and to reduce the num-
ber of rats employed.
Animals were housed in groups of two to four and inspected daily for infections or abnormal behaviour. They 
were allowed free access to both food and water for the entire duration of the experiments and housed under 
controlled temperature (22–25 °C) and humidity, with 12 h alternate light-dark cycles.
All animal care and experimental procedures were performed in strict accordance with the guidelines of the 
“Animal Care Committee” of the University of Modena and Reggio Emilia (Italy) that approved the study, and 
were in agreement with the directives of the “Italian Ministry of Health” (D.L. 116/92).
Rat surgery. Rats were subjected to the CCI technique developed by Bennett and Xie15. The experimental 
procedure involved the unilateral ligation of the sciatic nerve at the high-thigh level of the right hind paw. Rats 
were deeply anesthetized using ketamine (110 mg/Kg, i.p.) and xilazine (3.6 mg/Kg, i.p.). The cutting area was 
first shaved and then, under sterile precautions, the sciatic nerve was exposed. Proximal to its trifurcation, 4 
ligatures with 3-0 silk suture were tied loosely around the nerve at intervals of around 2 mm, so that the length of 
the treated nerve was approximately 8–10 mm, to preserve the epineurial circulation. The wound was closed with 
Figure 1. Treatment schedule. The number of rats/group is indicated. Light grey: saline treatment, dark grey: 
indomethacin treatment.
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three external stitches and disinfected. Sham-operation consisted in anesthesia and surgery up to sciatic nerve 
exposure without ligation. Within few hours after the surgery, rats with sciatic nerve ligation developed sponta-
neous pain manifested by guarding behaviour of the operated paw and licking on the injury side. In the following 
days, they showed signs of paw lifting and limping, excessive grooming and biting, that have been suggested as 
nocifensive signs indicating the presence of spontaneous pain24. Moreover, rats with sciatic nerve ligation exibited 
signs of allodynia to mechanical stimulation assessed by Von Frey test 2 and 5 weeks after surgery, compared to 
sham-operated rats (Supplementary Fig. 1). Pain indicator signals persisted for the entire duration of the experi-
ment. Autotomy was absent in all cases.
Serum sample preparation for proteomic analysis. Blood was collected during animal decapitation 
into vacutainer serum separation tubes, and allowed to clot at room temperature for 1 h. Serum was separated by 
centrifugation at 2000 × g for 10 min at + 4 °C. After the addition of a protease inhibitor cocktail (Sigma-Aldrich) 
to prevent protein enzymatic breakdown or modifications, samples were divided into aliquots and kept frozen 
at − 80 °C until use. To reduce the complexity of serum samples before proteomic analysis, they were treated with 
the ProteoPrep® Immunoaffinity albumin and IgG depletion kit (Sigma-Aldrich), that specifically removes the 
two most abundant serum proteins, albumin and IgG25. The protein content after depletion was assayed by the 
spectrophotometric Bradford’s method26, using bovine serum albumin (BSA) as standard.
SDS-PAGE and two-dimensional gel electrophoresis. The proteomic analysis was performed on 
depleted serum samples, first by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
and then by two-dimensional gel electrophoresis (2-DE). SDS-PAGE was carried out according to Laemmli’s 
procedure27, under reducing conditions. Serum samples (20 μ g of total proteins) were mixed with the 
2× Laemmli sample buffer (Bio-Rad) supplemented with 0.5% dithiothreitol (DTT). Sample mixtures were 
boiled at 95 °C for 5 min, and then loaded onto 12% polyacrylamide gels. The electrophoresis was achieved using 
1× Tris-glycine-SDS (TGS) running buffer pH 8.3 (Bio-Rad), initially at 100 V for 30 min, followed by an increase 
up to 200 V. Proteins were stained with colloidal Coomassie Blue G-250 by overnight incubation under gentle 
shaking, and finally destained with 10% methanol/5% acetic acid. Gels were done in triplicate and different per-
centage of acrylamide were tested to achieve the best resolution of protein bands. Gel images were acquired using 
a GS-800 calibrated densitometer (Bio-Rad) and analyzed by the “Quantity One 1-D Analysis Software” (version 
4.6.7, Bio-Rad), as previously reported28. In brief, this software detects differentially expressed proteins among 
different groups on the basis of band staining intensity, converting signals from samples into digital data, which 
are displayed as a gray-scale. The total band intensity is expressed as optical density (OD).
Serum samples were subjected also to 2-DE analysis. Proteins (80 μ g) were first diluted with rehydration buffer 
(6 M urea, 2 M thiourea, 4% CHAPS, 25 mM DTT, 0.2% ampholytes) and then loaded onto 7 cm immobilized pH 
gradient (IPG) strips, pH 3–10 (Ready Strip™ , Bio-Rad). Proteins were separated by isoelectro focusing (IEF) at 
20 °C, by an initial passive step of rehydration for 16 h, followed by a second IEF step at 500 V for 30 min, next 
ramping up to 5000 V for 5 h and finally focusing to reach 60000 V-h. Afterwards, the equilibration step and 
second-dimension separation were performed as previously reported in detail28. Finally, protein spots were vis-
ualized according to the Coomassie blue staining protocol described above. Gels were done at least in triplicate, 
testing different pH range of the strips and percentage of acrylamide in the second-dimension, to obtain the 
best spot resolution. Gel images were acquired by a calibrated densitometer and analyzed by the “PDQuest 2-D 
analysis software” program (version 7.3.1, Bio-Rad). This software compares bi-dimensional gel images to reveal 
increased or decreased protein spots based on their staining intensity, as previously described10. The abundance 
changes, both for the protein bands and for the spots, are shown in tables as fold-change of protein signal, cal-
culated as ratio between the spot intensitiy values in CCI-saline or CCI-indomethacin vs sham-operated saline.
Protein identification by mass spectrometry. The differential bands and spots were excised from the 
gels and subjected to an “in-gel” trypsin digestion protocol as previously reported28, prior to mass spectrom-
etry (MS) analysis. The peptide mixtures were analyzed by a Nano LC-Chip-MS System, formed by the 6520 
Accurate-Mass Quadrupole-Time of Flight Liquid Chromatography/Mass Spectrometry (Q-ToF LC/MS) coupled 
with a 1200 Nano HPLC-Chip microfluidic device (Agilent Technologies, CA, USA), as previously described25. 
Protein-identification peak lists were generated using MASCOT search engine (http://mascot.cigs.unimore.it/
mascot), selecting the UniProtKB database.
Quantitative real-time polymerase chain reaction. After animal decapitation, striatum and lumbar 
spinal cord were dissected out, lysed by mechanical disruption in Trizol reagent (Qiagen), homogenized following 
the procedure provided by the manufacturer (RNeasy Plus Mini Kit, Qiagen) and processed for quantitative PCR 
(qPCR) as described29. Isolated mRNA was reverse transcribed to cDNA using random hexamers and M-MLV 
Reverse Transcriptase (Promega Corporation) following the instructions provided by the manufacturer. Samples 
were heated at 70 °C for 5 min to eliminate any secondary structures, then incubated at 23 °C for 10 min, 1 h at 
37 °C, and 5 min at 95 °C before being chilled at 4 °C using a thermocycler T Gradient (Whatman, Biometra). The 
amount of cDNA was quantified with iTaq Universal SYBR Green Supermix (Bio-Rad) using a Bio-Rad RT-PCR 
iCycler. Each PCR reaction was performed in triplicate using 150 nM of each primer, 10 μ L of iTaq Universal 
SYBR Green Supermix (Bio-Rad), cDNA and nuclease-free water with the following cycling parameters: 10 min 
at 95 °C and 40 cycles of 1 min at 95 °C, 1 min at 60 °C and 1 min at 72 °C, followed by a melting curve analysis. 
RT-PCR primers were designed in two different exons; primer length was comprised between 18 and 30 bp, GC 
content was between 40 and 60% and nonspecific primer annealing and mismatches were minimized. The pres-
ence of nonspecific products of amplification and primer-dimers was evaluated by melting curve analysis during 
RT-PCR primer validation. The following primers were used to amplify the transcripts of interest:
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GADPH Fw: 5′-CATCAAGAAGGTGGTGAAGC-3′ 
GADPH Rv: 5′-ACCACCCTGTTGCTGTAG-3′ 
PTGDS Fw: 5′-CAAGACAAGTTCCTGGGGCG-3′ 
PTGDS Rv: 5′-GTGCCAGACAGTGGTAGCTC-3′ 
TTR Fw: 5′-TCGATGTGGCCGTGAAAGTG-3′ 
TTR Rv: 5′-CGGAAGGGGTGTACAGGGTA-3′ 
APOE Fw: 5′-TTGGTCCCATTGCTGACAGG-3′ 
APOE Rv: 5′-GCGCAGGTAATCCCAGAAGC-3′ 
APOA1 Fw: 5′-TCTTCCTGACAGGTTGCCAAG-3′ 
APOA1 Rv: 5′-TGGCGAAATCCTTCACCCTG-3′ 
A1M Fw: 5′-GGACAGACAGTGAAATTCCGAG-3′ 
A1M Rv: 5′-GCAGTCCTCCTGGTAGATCG-3′ 
VDBP Fw: 5′-GGAAAGGAAAAATCAAGGATGAGCC-3′ 
VDBP Rv: 5′-ATGTGTGTTCAGGCAGCTCTC-3′ 
APOA4 Fw: 5′-CCAAGGAGGCTGTGGAACAA-3′ 
APOA4Rv: 5′-CACTCAGTTGAACGGCGAAG-3′ 
All the primers were shown to efficiently recognize their target mRNA using as positive controls spinal cord 
tissue (APOA1, APOE, PTGDS, VDBP), hypothalamus (TTR)30 or liver (APOA4, A1M).
Fold differences of expression were calculated using the comparative method, also referred as Δ Δ Ct method29. 
The sample of sham-operated saline was used as the reference sample or calibrator.
Data analysis. All data are presented as mean ± standard error of the mean. Statistical comparisons were 
performed using the 2-way analysis of variance (ANOVA), considering a p-value ≤ 0.05 as statistically significant.
Results
SDS-PAGE analysis of serum proteins. The densitometric analysis by QuantityOne software revealed 
several bands differentially expressed (Fig. 2). These bands were cut from the gel and analysed by MS. Six pro-
tein bands appeared increased (2 to 5-fold) in the group of CCI rats treated with saline 5 weeks after the surgery 
Figure 2. SDS-PAGE protein profile of depleted serum. The lanes report: MW marker, Molecular 
Weight protein ladder (BenchMark); Sham-op saline = sham-operated group treated with saline; sham-op 
indomet. = sham-operated group treated with indomethacin; CCI-saline = ligated group treated with saline; 
CCI-indomet. = ligated group treated with indomethacin, at 2 and 5 weeks post-surgery. The protein bands 
differentially expressed between the different groups analysed by Q-ToF LC/MS are enclosed in rectangles: 
A1AT: Alpha-1-antitrypsin, VDBP: Vitamin-D binding protein, APOA4: Apolipoprotein A-IV, KCRM: 
Creatine kinase M-type, HPT: Haptoglobin, APOE: Apolipoprotein E, CRP: C-reactive protein, APOA1: 
Apolipoprotein A-I, GPX3: Glutathione peroxidase 3, PRDX2: Peroxiredoxin-2.
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compared to sham-operated rats treated with saline, whereas one of these bands was already increased in CCI rats 
2 weeks after surgery. These changes were partially reversed by indomethacin treatment (Table 1).
The MS analysis of rat serum at 5 weeks post-surgery identified the following proteins, listed in Table 1: 
alpha-1-antitrypsin (A1AT), vitamin D-binding protein (VDBP), apolipoprotein A-IV (APOA4), creatine kinase 
M-type (KCRM), haptoglobin (HPT), apolipoprotein E (APOE), C-reactive protein (CRP), apolipoprotein A-I 
(APOA1), and 2 enzymes, glutathione peroxidase 3 (GPX3) and peroxiredoxin-2 (PRDX2). The protein band 
containing HPT and APOE was increased also in CCI rats treated with saline 2 weeks after surgery (Fig. 2, 
Table 1).
In Table 1, only the proteins showing the highest ion score and peptide match, as well as the greater sequence 
coverage obtained by MASCOT search engine (MS/MS ion search) through the UniProtKB database, are 
reported. The score is calculated as [−10 × log(P)], where P is the probability that the observed match between 
the experimental data and the database sequence is a random event; the peptide match refers to the total number 
of peptides that matched the identified protein; the sequence coverage indicates the percentage of amino acids 
sequenced for the detected protein. In addition, another parameter that was taken into account for protein selec-
tion was the MW; proteins with MW not conforming with those indicated by the MW marker standard were not 
considered.
Two-dimensional gel electrophoresis of serum proteins. The 2-DE coupled to MS analysis con-
firmed some of the data obtained by SDS-PAGE and permitted to identify and estimate by means of the PDQuest 
image analysis software (Bio-Rad) further differentially-expressed proteins at both 2 and 5 week time inter-
vals (Figs 3 and 4, Table 2 and 3, respectively). At 2 weeks post-surgery, the level of 3 proteins was increased 
9–10.5-fold in the group of CCI-saline compared to sham-operated rats treated with saline: VDBP, APOA4, 
and alpha-1-macroglobulin (A1M). Acute indomethacin treatment completely reversed this increase (Fig. 3 and 
Table 2).
At 5 weeks post-surgery, the levels of two of the proteins identified at 2 weeks post-surgery, VDBP and A1M, 
were still increased (about 8.5 and 6-fold increase, respectively) in CCI-saline with respect to sham-operated 
rats treated with saline. In addition, the levels of 4 additional proteins were increased in ligated rats treated 
with saline, corresponding to prostaglandin-H2 D-isomerase (PTGDS, 7.5-fold increase), transthyretin (TTR, 
20-fold increase), APOA1 (22.5-fold increase) and APOE (3.3-fold increase), as illustrated in Fig. 4 and defined in 
Table 3. Chronic indomethacin treatment could substantially revert these increases with the exception of APOE 
whose levels remained elevated.
Quantitative PCR analysis of central nervous tissues. Proteins whose levels are increased in the 
serum of ligated rats may derive from multiple sources in the body. A distinct possibility is that some of them 
derive from the lumbar spinal cord at the level of sciatic nerve root entry. To test this hypothesis, by using qPCR, 
we measured in the lumbar spinal cord the mRNA levels of 7 proteins whose levels were found to be altered in 
the serum of the same animals. Three of the transcripts, TTR, APOA4 and A1M, were not detected in the lumbar 
spinal cord. Instead, PTGDS, APOE, APOA1 and VDBP were detected in the extract from lumbar spinal cord 
Entry 
name(a) Protein full name
Gene 
name
Acc. 
number(b)
MW 
(kDa)(c) Score(d)
Peptide 
Match(e)
Seq. 
cov(f). emPAI(g)
Fold 
change(h)
Fold 
change(i)
2 weeks after surgery
HPT Haptoglobin Hp P06866 39.1 603 170 28% 1.65
+ 2.0 + 1.3
APOE Apolipoprotein E Apoe P02650 35.8 219 44 27% 0.30
5 weeks after surgery
VDBP Vitamin D-binding protein Gc P04276 55.1 1568 128 61% 4.71 + 2.2 + 1.5
A1AT Alpha-1-antiproteinase Serpina1 P17475 46.3 4400 318 57% 11.8
APOA4 Apolipoprotein A-IV Apoa4 P02651 44.4 2450 132 76% 7.01
+ 2.9 + 1.9
KCRM Creatine kinase M-type Ckm P00564 43.2 1054 42 24% 1.09
HPT Haptoglobin Hp P06866 39.1 1477 156 43% 1.65
+ 3.2 + 2.9
APOE Apolipoprotein E Apoe P02650 35.8 382 43 44% 1.22
CRP C-reactive protein Crp P48199 25.7 3117 367 36% 1.35 + 2.5 + 2.1
APOA1 Apolipoprotein A-I Apoa1 P04369 30.1 776 74 65% 6.34 + 2.1 + 1.5
GPX3 Glutathione peroxidase 3 Gpx3 P23764 25.6 833 77 43% 2.84
+ 5.0 + 2.1
PRDX2 Peroxiredoxin-2 Prdx2 P35704 21.9 138 12 30% 0.53
Table 1.  Differentially expressed proteins revealed by SDS-PAGE and identified by Q-ToF LC/MS. 
(a)Protein entry name from UniProt knowledge database (all with extension_RAT). (b)Protein accession number 
(UniProtKB database). (c)Theoretical protein molecular weight. (d)The highest scores obtained with MASCOT 
search engine. (e)Total number of peptides matching the identified protein. (f)Percentage of amino acids 
sequenced for the detected protein. (g)Exponentially modified protein abundance index. (h)Fold-change: protein 
total band intensity change in CCI-saline vs sham-operated saline. (i)Fold-change: protein total band intensity 
change in CCI-indomethacin vs sham-operated saline.
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and differentially expressed in the different treatment groups. As regards PTGDS, no significant difference was 
detected between the 2 week post-surgery treatment groups (two-way ANOVA, lesion F(1,11) = 2.051, p = 0.180; 
drug F(1,11) = 0.566, p = 0.467; lesion × drug F(1,11) = 0.161, p = 0.696), whereas, at 5 weeks post-surgery, a 
significant increase by about 9-fold was present in CCI rats chronically-treated with saline, that was markedly 
reduced by indomethacin treatment (two-way ANOVA, lesion F(1,18) = 6.486, p = 0.020; drug F(1,18) = 4.409, 
p = 0.050; lesion × drug F(1,18) = 4.455, p = 0.049) (Fig. 5).
A similar, though less intense effect (about 5-fold) was detected for APOE (two-way ANOVA, 2 week treat-
ments: lesion F(1,11) = 0.996, p = 0.340; drug F(1,11) = 0.134, p = 0.721; lesion × drug F(1,11) = 1.136, p = 0.309; 
5 week treatment: lesion F(1,18) = 9.952, p = 0.006; drug F(1,18) = 4.204, p = 0.057; lesion × drug F(1,18) = 5.690, 
p = 0.030) (Fig. 5).
A different pattern of effect was instead detected for APOA1 and VDBP mRNAs. At 2 weeks post-surgery, 
a significant, though modest, effect of ligation was detected that was not reverted by indomethacin treatment 
(two-way ANOVA, APOA1: lesion F(1,11) = 5.093, p = 0.045; drug F(1,11) = 1.587, p = 0.234; lesion × drug 
F(1,11) = 0.402, p = 0.539; VDBP: lesion F(1,11) = 5.016, p = 0.047; drug F(1,11) = 0.001, p = 0.970; lesion × drug 
F(1,11) = 0.009, p = 0.926). At 5 weeks post-surgery, significant increases by about 6- and 9-fold for APOA1 
and VDBP, respectively, were present in CCI rats, that were reduced by indomethacin treatment (two-way 
ANOVA, APOA1: lesion F(1,18) = 6.384, p = 0.022; drug F(1,18) = 2.648, p = 0.123; lesion × drug F(1,18) = 4.569, 
p = 0.048; VDBP: lesion F(1,18) = 6.288, p = 0.024; drug F(1,18) = 2.836, p = 0.113; lesion × drug F(1,18) = 3.813, 
p = 0.070) (Fig. 5).
As a control, we measured the levels of the same 7 mRNAs in the striatum. In this region, 5 out of the 7 tran-
scripts we have considered (TTR, APOA4, A1M, APOA1 and VDBP) were not detected. APOE and PTDGS were 
detected at levels, respectively, comparable to and lower than those of the lumbar spinal cord. As regards both 
APOE and PTGDS, no significant difference was detected between any treatment group 5 weeks after surgery 
(APOE: lesion F(1,23) = 0.786, p = 0.385; drug F(1,23) = 1.005, p = 0.326; lesion × drug F(1,23) = 0.009, p = 0.925; 
PTGDS: lesion F(1,22) = 0.554, p = 0.464; drug F(1,22) = 0.549, p = 0.467; lesion × drug F(1,22) = 0.193, 
p = 0.665) (Supplementary Fig. 2).
Figure 3. Representative 2D gel images for the 2 week time interval after surgery. First-dimension 
separation was obtained by IPG strip, pH range 3–10; second-dimension separation was achieved by 8–16% 
gradient gel. (A) sham-operated group treated with saline, (B) sham-operated group treated with indomethacin, 
(C) CCI-saline, (D) CCI-indomethacin. In panel C, rectangles indicate the increased proteins vs panel D, 
identified by MS and listed in Table 2 (VDBP: Vitamin D-binding protein, APOA4: Apolipoprotein A-IV, A1M: 
Alpha-1-macroglobulin).
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Discussion
The main result of this study is the identification by means of a proteomic approach of several serum proteins 
that are markedly overexpressed in the CCI model of sciatic nerve ligation in the rat. Protein overexpression 
was partially different at 2 and 5 weeks post-surgery and was sensitive to indomethacin treatment. More specifi-
cally, A1M, APOA4 and VDBP levels were markedly increased 2 weeks after nerve ligation; while APOA4 levels 
declined to sham-operated control levels, A1M and VDBP levels remained increased at 5 weeks post-surgery. 
Moreover, at this latter time point, increased levels of a further set of proteins was detected: APOA1, APOE, 
PTGDS and TTR. In addition, we started a search for the possible source(s) in the body of serum proteins shown 
here to be overexpressed. We focused our investigation on the lumbar spinal cord, the site of origin and termina-
tion of the motor and sensory components, respectively, of the sciatic nerve, and the striatum, an unrelated brain 
region, where we measured by qPCR transcript levels of 7 proteins previously shown to be overexpressed at the 
proteomic analysis. Four of these transcripts, APOA1, APOE, PTGDS and VDBP, were expressed in the spinal 
cord and were markedly and selectively increased in CCI-saline 5 weeks after surgery. No significant change in 
any of the transcripts was observed in the striatum. The lumbar spinal cord is therefore a possible source of several 
proteins found increased in the serum of rats 5 weeks after sciatic nerve ligation.
Previous studies have shown that signs of hyperalgesia and alterations related to nerve degeneration/regenera-
tion processes differ at different time intervals from sciatic nerve ligation. In the CCI model, signs of hyperalgesia 
such as duration of lesioned paw lifting in several pain tests (neutral plate, hot plate, pin prick, acetone spray or 
cold plate) as well as resistance to pressure at the Von Frey test, remained constant at 2 and 5 weeks post-ligation21, 
and were similar, or slightly lower, with respect to the first days post-surgery, indicating that hyperalgesia level 
is substantially maintained between 2 and 5 weeks post-ligation. On the other hand, the study of degenerative/
regenerative processes of the ligated sciatic nerve showed a complex pattern of post-surgery changes22. Massive 
wallerian degeneration of mylelinated fibers, together with loss of unmyelinated fibers and synpathetic fibers, 
peaked during the second week post-ligation. While attenuated signs of nerve degeneration persisted in the fol-
lowing weeks up to 15 weeks post-ligation, starting from the third week signs of progressive nerve regenera-
tion were detected, so that at 5 weeks post-ligation several nerve morphological features had partially recovered. 
Accordingly, sensory and motor nerve conduction velocities started to recover 2 weeks after the injury31. It is 
Figure 4. Representative 2D gel images for the 5 week time interval after surgery. First-dimension 
separation by IPG strip, pH range 3–10, second-dimension separation by 8–16% gradient gel. (A) sham-
operated group treated with saline, (B) sham-operated group treated with indomethacin, (C) CCI-saline, 
(D) CCI-indomethacin. In panel C, rectangles indicate the increased proteins vs panel D, identified by MS and 
listed in Table 3 (VDBP: Vitamin D-binding protein, A1M: Alpha-1-macroglobulin, APOA1: Apolipoprotein 
A-I, PTGDS: Prostaglandin-H2 D-isomerase, TTR: Transthyretin, APOE: Apolipoprotein E).
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noteworthy that most instances of overexpression of serum protein and corresponding spinal mRNA levels were 
not observed at 2 weeks post-ligation, a period when the peak of degenerative processes was detected, but at 5 
weeks post-ligation when intense signs of regeneration were (also) detected.
The proteins that we found overexpressed 2 and/or 5 weeks after sciatic nerve ligation have been previously 
implicated in pain, inflammatory or regenerative processes.
A1M belongs to the alpha macroglobulins family, a group of large glycoproteins that inhibit all types of pro-
teinases by a trapping mechanism32. This protein was found overexpressed at both 2 and 5 weeks post-injury and 
may have different functions. In fact, it was found to be up-regulated in models of acute inflammation33–35 and has 
been involved in nerve regeneration, as it was shown to stimulate neurite outgrowth of embryonic cerebral cor-
tical neurons in vitro and rat sciatic nerve regeneration in vivo, as well as nerve growth factor-promoted neurite 
outgrowth in pheochromocytoma PC12 cells36.
In CCI-rats we detected the overexpression of several apolipoproteins, i.e., APOA4, APOA1 and APOE. 
During nerve regeneration, large amounts of lipids are required for axonal regeneration and remyelination. It is 
thought that lipoproteins originating from axon and myelin breakdown in injured peripheral nerves supply cho-
lesterol to regenerating axons37. Accordingly, increased levels of four apolipoproteins, including APOD, APOA4, 
APOA1 and APOE, were found in extracts of injured sciatic nerve, thus proving their accumulation in the regen-
erating peripheral nerves12,38,39. In our study, by 2-DE analysis we found increased serum levels of APOA4 selec-
tively at 2 weeks after surgery, while APOA1 and APOE were found overexpressed selectively at 5 weeks after 
surgery. This is in broad accordance with Jiménez et al.12 who showed that APOA4 is transiently increased after 
injury, whereas APOA1 and APOE have a progressive increase up to 35 days after injury. As mentioned above, 
after nerve injury the request of lipids increases, and apolipoproteins from various sources play a pivotal role in 
the requested cholesterol transfer39. Probably, APOA4 is produced in the early stage of damage, during nerve 
degeneration in response to denervation. Afterwards, as remyelination and regeneration processes begin (in the 
second and third week after injury), and concurrently Schwann cells deplete their cholesterol stores39, the lipid 
transport system becomes more active. Consequently, further proteins increase, such as APOA1 and APOE. This 
latter is a 34 kDa glycoprotein known to influence degenerative, as well as regenerative events in the peripheral 
nervous system40. After peripheral nerve injury, axons degenerate and Schwann cells reabsorbe myelin; at the 
same time, APOE synthesis by resident and monocyte-derived macrophages and by endothelial cells increase 
greatly, leading to APOE accumulation within the nerve39,41,42. All these reports support the concept that APOE is 
involved in re-utilization of cholesterol from degenerating nerves for axonal repair and reconstruction of axonal 
Entry 
name(a) Protein full name
Acc. 
number(b)
Gene 
name MW (Da) Score(c)
Peptide  
match/sig. match(d) Seq/ sig. seq(e) Seq. cov(f). emPAI(g)
Fold 
change(h)
Fold 
change(i)
VDBP Vitamin D-binding protein P04276 Gc 55106 2546 239/161 33/28 61% 7.09 + 9.2 0.94
APOA4 Apolipoprotein A-IV P02651 Apoa4 44429 3168 256/157 40/29 83% 14.27 + 10.6 + 1.03
A1M Alpha-1-macroglobulin Q63041 A1m 168388 4186 229/162 18/15 13% 2.39 + 10.4 0.79
Table 2.  Serum proteins differentially expressed 2 weeks post-surgery by 2-DE analysis in the group of 
CCI-saline and identified by Q-ToF LC/MS. (a)Protein entry name (all with extension_RAT) from UniProtKB 
database, conforming to Fig. 3. (b)Primary accession number from UniProtKB database. (c)The highest scores 
by MASCOT search engine. (d)Total number of matched peptides and the significant matches. (e)Total number 
of sequences and the number of significant sequences. (f)Percentage of amino acids sequenced for the detected 
protein. (g)Exponentially modified protein abundance index. (h)Protein spot intensity change in CCI-saline vs 
sham-operated saline. (i)Protein spot intensity change in CCI-indomethacin vs sham-operated saline.
Entry 
name(a) Protein full name
Acc. 
number(b)
Gene 
name MW (Da) Score(c)
Peptide  
match/sig. match(d) Seq/ sig. seq(e) Seq. cov(f). emPAI(g)
Fold 
change(h) Fold change(i)
VDBP Vitamin D-binding protein P04276 Gc 55106 642 52/37 14/10 30% 1.01 + 8.5 0.96
A1M Alpha-1-macroglobulin Q63041 A1m 168388 4989 299/218 17/15 13% 0.62 + 6.1 0.84
APOA1 Apolipoprotein A-I P04639 Apoa1 30100 1083 90/69 23/20 59% 14.29 + 22.6 + 1.92
PTGDS Prostaglandin-D H2-isomerase P22057 Ptgds 21301 709 42/36 6/5 31% 3.71 + 7.6 + 1.45
TTR Transthyretin P02767 Ttr 15824 750 45/32 11/8 59% 7.42 + 20.4(j) no detect(k).
APOE Apolipoprotein E P02650 Apoe 35788 4187 230/182 27/20 64% 14.63 + 3.3 + 2.8
Table 3. Serum proteins differentially expressed 5 weeks post-surgery by 2-DE analysis in the group of 
CCI-saline and identified by Q-ToF LC/MS. (a)Protein entry name (all with extension_RAT) from UniProtKB 
database, conforming to Fig. 4. (b)Primary accession number from UniProtKB database. (c)The highest scores 
by MASCOT search engine. (d)Total number of matched peptides and the significant matches. (e)Total number 
of sequences and the number of significant sequences. (f)Percentage of amino acids sequenced for the detected 
protein. (g)Exponentially modified protein abundance index. (h)Protein spot intensity change in CCI-saline vs 
sham-operated saline. (i)Protein spot intensity change in CCI-indomethacin vs sham-operated saline. (j)Fold 
change was calculated towards CCI-indomethacin since sham-operated rats had no detectable spot. (k)Fold 
change was not calculated since sham-operated rats had no detectable spot.
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and myelin membranes (regeneration process)37,43. These sets of evidence point to a potential role of APOE in 
functional recovery and/or reduction of neuropathic pain after peripheral nerve damage44.
TTR (also called prealbumin) is an ubiquitous protein, present in both the cerebrospinal fluid and serum, 
with a specific role in the transport of thyroid hormones and, indirectly, of retinol45; it is highly expressed in 
choroid plexus epithelial cells and has been detected in retina pigment epithelium and in the liver (UniProtKB 
database). TTR is not thought to be expressed by neurons (present data) (Allen Mouse Brain Atlas (ABA), 
http://mouse.brain-map.org)46, but is expressed by Schwann cells47. Increased levels of TTR in CCI-saline rats 5 
weeks post-surgery may be related to regeneration processes. An involvement of TTR has been reported in senso-
rimotor, post-traumatic nerve fiber regeneration, axonal growth enhancement during peripheral nervous system 
regeneration, and neuroprotection in Alzheimer’s disease48–50.
Another protein overexpressed 5 weeks after surgery in CCI-saline rats is PTGDS; its overexpression may be 
particularly relevant as a pathogenic mechanism for production and/or maintenance of hyperalgesia. PTGDS, 
also known as β-trace protein, is a glutathione-independent prostaglandin D synthase that catalyzes the conver-
sion of prostaglandin H2 (PGH2) to prostaglandin D2 (PGD2) and is involved in various physiological functions, 
such as vasodilation, thermoregulation, smooth muscle contraction and relaxation, sleep induction and sedation, 
regulation of immune response, mediation of cellular homeostasis and modulation of nociception51,52. PGD2 
represents the most abundant prostanoid produced in CNS of mammals53. Some studies conducted on animal 
models have proved that prostaglandins play fundamental roles in central sensitization at spinal level, resulting in 
induction of hyperalgesia and cutaneous allodynia54,55. In particular, it has been reported that PTGDS-deficient 
mice lack tactile pain and allodynia56, and have reduced pain hypersensitivity57.
VDBP was overexpressed both at 2 and 5 weeks after nerve injury in CCI-saline vs sham-operated saline. 
VDBP is a major plasma constituent in a broad range of animal species. It is a monomeric glycoprotein syn-
thesized and secreted by the liver, which transports vitamin D sterols and metabolites58. It has other functions, 
including the ability to bind monomers of actin with high affinity, sequestering them from polymerization, and to 
associate with membrane-bound immunoglobulins on the surface of B-lymphocytes59. Of relevance in the pres-
ent context is the possible involvement of VDBD and vitamin D in nerve regeneration60,61 and pain mechanisms. 
In fact, vitamin D is thought to influence pain manifestation, playing a role in the aetiology and maintenance of 
CP states and associated comorbidities62. Interestingly, it has been demonstrated that vitamin D inadequacy is 
associated with medication refractory muscoloskeletal pain and neuromuscolar dysfunction among patients with 
CP63, and treatment with vitamin D can alleviate pain in a majority of the patients with vitamin D deficiency64. 
In addition, another study reported a possible relationship between dysfunction of VDBP and migraine attacks65.
To sum up, while the changes in A1M, TTR, APOA4, APOA1 and APOE may participate to nerve cell regen-
eration through local supplementation of lipids and other unknown mechanisms, alterations in VDBP and 
Figure 5. Levels of APOA1, APOE, PTGDS and VDBP mRNA in the lumbar spinal cord. The levels of 
APOA1, APOE, PTGDS and VDBP mRNA were measured in the lumbar spinal cord of rats, 2 or 5 weeks after 
a CCI of the sciatic nerve. The data were analysed by means of two-way ANOVA with sham-operation/ligation 
and saline/indomethacin as factors, showing a significant interaction for all 4 mRNAs in the 5 week groups.
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PTGDS may play a pathogenic role in the mechanisms of central pain hypersensitivity. In particular, spinal pro-
duction of PGD2 is thought to cause hyperalgesia and allodynia66.
Previous proteomic studies in biological liquids, such as urine10,11, cerebrospinal fluid9,67, muscle interstitial 
fluid68 of subjects suffering CP reported increased levels of most of the proteins that we found overexpressed 
in the serum of rats 5 weeks after ligation, including PTGDS9,11,67, TTR9,10,68, APOE9, VDBP67 and APOA19,68. 
This evidence points to CCI at late post-surgery time intervals as a highly relevant animal model of human CP 
states. Indeed, it suggests that proteomic markers found in human studies do not reflect hyperalgesic states per se 
but rather are associated to CP states where chronic degenerative and regenerative processes coexist in affected 
nerves. The isomorphism between animal model and human pathological state opens up the possibility to study 
in depth and mechanistically the origin and function of these proteins and attribute them a role as markers of 
specific features of CP and related pathologies.
Notably, an acute or chronic (3 weeks) treatment with indomethacin was able to reverse most of the observed 
changes in protein expression at 2 or 5 weeks post-surgery. This evidence suggests that the processes leading to the 
observed CCI-induced increases in serum proteins are controlled by molecular targets modulated by indomethacin, 
a powerful NSAID with non-selective inhibitory activity on cyclooxygenase 1 and 223. Besides common NSAID-like 
effects, indomethacin is thought to have specific, though not well known, pharmacological actions as suggested by 
the existence of a set of diseases involving CP that are exquisitely responsive to indomethacin69. Comparison of sev-
eral NSAIDs in the present paradigm may help define possible selective actions and targets of NSAIDs in CP states.
In conclusion, using an animal model of chronic neuropathic pain, this study demonstrates an increased 
expression of specific serum proteins, several of which were shown to be overexpressed in biological fluids of 
patients suffering CP. This close correspondence between proteins overexpressed in biological fluids of patients 
with CP and rats with chronic neuropathic pain opens up the possibility of an in depth study of the origin and 
pathophysiological significance of CP biomarkers.
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Supplementary figure 1 
Allodynia in sham-operated rats and CCI rats 2 or 5 weeks after surgey evaluated by means of the 
Von Frey test. All CCI rats showed signs of allodynia at both 2 and 5 weeks post-surgery. 
Statistical analysis according to two-way ANOVA. 
2 weeks: CCI/sham, F(1,35) = 4.377, p=0.044; saline/indomethacin, F(1,35) = 1.342, p=0.255; 
interaction, F(1,35) = 1.464, p=0.234. 
5 weeks: CCI/sham, F(1,30) = 10.096, p=0.003; saline/indomethacin, F(1,35) = 1.400, p=0.246; 
interaction, F(1,35) = 2.213, p=0.147. 
 
 
Supplementary figure 2 
Levels of APOE and PTGDS mRNA in the striatum of rats 5 weeks after sham-operation or a CCI of the 
sciatic nerve.  
The data were analysed by means of two-way ANOVA with sham-operation/ligation and 
saline/indomethacin as factors, showing no significant effect. 
 
 
 
 
 
 
 
 
 
 
 
Supplementary method 
Von Frey hair test. Mechanical sensitivity (allodynia) was assessed by Von Frey hair test, based 
on the responsiveness of the operated hind paw to the application of a series of von Frey filaments 
(Aesthesio®, USA), progressively increasing the stifness (ranging from 0.008 to 300 g). Animals 
were placed in a plexiglass cage with a metal grid floor, allowing them to move freely. Filaments 
were applied to the mid-plantar surface of both the operated and non-injured hindpaw. The smallest 
filament that elicited a foot withdrawal response was considered the threshold stimulus. Withdrawal 
thresholds at the contralateral (non-injured) side remained constant throughout the experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
